SCHEMBL1159623

SCHEMBL1159623

COc1cc(C=O)ccc1Br

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.68
TSHR P16473 1/20 0.68
TRIM24 O15164 1/20 0.61
HPGD P15428 1/20 0.61
ALDH5A1 P51649 1/20 0.61
ABAT P80404 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
TRIM33 Q9UPN9 1/20 0.61
FDPS P14324 1/20 0.58
AOX1 Q06278 1/20 0.56
SMN1; SMN2 Q16637 4/20 0.55
MAPT P10636 3/20 0.55
HTT P42858 2/20 0.55
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
TTR P02766 1/20 0.53
ALDH1A3 P47895 1/20 0.51
PRKDC P78527 1/20 0.50
ERN1 O75460 1/20 0.49
CYP2A6 P11509 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL155784 0.84 ALDH1A1 (0.68) ALDH1A1TSHRTRIM24HPGDALDH5A1
SCHEMBL29723752 0.84 ALDH1A1 (0.68) ALDH1A1TSHRTRIM24HPGDALDH5A1
SCHEMBL30882827 0.83 ALDH1A1 (0.73) ALDH1A1TSHRTRIM24HPGDALDH5A1
SCHEMBL28988638 0.82 XDH (0.66) ALDH1A1TSHRTRIM24HPGDALDH5A1
SCHEMBL29130913 0.82 TUBB1 (0.47) ALDH1A1TSHRTRIM24HPGDALDH5A1
3,4-Dimethoxybenzaldehyde SCHEMBL1330962 0.81 ALDH1A1 (1.00) ALDH1A1TSHRTRIM24HPGDALDH5A1
3,4-Dimethoxybenzaldehyde SCHEMBL5308959 0.81 ALDH1A1 (1.00) ALDH1A1TSHRTRIM24HPGDALDH5A1
3,4-Dimethoxybenzaldehyde SCHEMBL25202 0.81 ALDH1A1 (1.00) ALDH1A1TSHRTRIM24HPGDALDH5A1
3,4-Dimethoxybenzaldehyde SCHEMBL29364994 0.81 ALDH1A1 (1.00) ALDH1A1TSHRTRIM24HPGDALDH5A1
SCHEMBL24925872 0.80 FDPS (0.50) ALDH1A1TSHRTRIM24HPGDALDH5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116891471-A Preparation method of non-neridrone bulk drug 江苏德源药业股份有限公司 2023-10-17 CN claimed
EP-4565562-B1 PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES NXERA PHARMA UK LTD (GB) 2026-05-27 EP disclosed
EP-4519384-B1 PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF PROMEGA CORP (US) 2026-04-29 EP disclosed
US-12583839-B2 PD-L1 antagonist compound ADLAI NORTYE BIOPHARMA CO., LTD. (CN) 2026-03-24 US disclosed
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12559504-B2 Benzotriazole derivative UBE CORPORATION (JP) 2026-02-24 US disclosed
US-20260042745-A1 PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES NXERA PHARMA UK LIMITED (GB) 2026-02-12 US disclosed
CN-121449609-A Preparation method of non-neridrone bulk drug 江苏海洋大学 2026-02-03 CN disclosed
EP-4680336-A1 AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF Ventus Therapeutics U.S., Inc. (US) 2026-01-21 EP disclosed
EP-4676591-A2 SMALL MOLECULE FSH RECEPTOR MODULATORS Ferring B.V. (NL) 2026-01-14 EP disclosed
US-20060116401-A1 Antibacterial compounds ASTRAZENECA AB (SE) 2006-06-01 US disclosed
EP-1567521-A1 ANTIBACTERIAL COMPOUNDS AstraZeneca AB (SE) 2005-08-31 EP disclosed
US-6849619-B2 Substituted pyridoindoles as serotonin agonists and antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2005-02-01 US disclosed
US-20040186094-A1 Substituted pyridoindoles as serotonin agonists and antagonists BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-09-23 US disclosed
WO-2004048370-A1 ANTIBACTERIAL COMPOUNDS ASTRAZENECA AB (SE) 2004-06-10 WO disclosed
US-6699852-B2 ANTISEROTONIN AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS; ANTIDEPRESSANTS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-03-02 US disclosed
EP-1343791-A2 SUBSTITUTED TETRACYCLIC PYRIDOINDOLES AS SEROTONIN AGONISTS AND ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-09-17 EP disclosed
US-20020173503-A1 Substituted pyridoindoles as serotonin agonists and antagonists BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-11-21 US disclosed
WO-2002059129-A2 SUBSTITUTED TETRACYCLIC PYRIDOINDOLES AS SEROTONIN AGONISTS AND ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-08-01 WO disclosed
US-4024274-A Benzylamine derivatives and process for preparing them HOECHST AKTIENGESELLSCHAFT (DT) 1977-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559504-B2 Benzotriazole derivative KEAP1, NFE2L2, NCOR1 ALDH1A1 198/4885TSHR 2245/4885TRIM24 1335/4885
US-20020173503-A1 Substituted pyridoindoles as serotonin agonists and antagonists HTR1A, HTR1B, HTR7 ALDH1A1 2258/4885TSHR 305/4885TRIM24 4387/4885
US-20040186094-A1 Substituted pyridoindoles as serotonin agonists and antagonists HTR1A, HTR1B, HTR7 ALDH1A1 2258/4885TSHR 305/4885TRIM24 4387/4885
US-20060116401-A1 Antibacterial compounds MRPL21, NR0B2, CYP8B1 ALDH1A1 927/4885TSHR 1360/4885TRIM24 4684/4885
US-20260042745-A1 PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES PTGER4, PTGER1, PTGER2 ALDH1A1 1803/4885TSHR 196/4885TRIM24 4626/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 ALDH1A1 3094/4885TSHR 204/4885TRIM24 4494/4885
US-12583839-B2 PD-L1 antagonist compound CD274, PDCD1LG2, PDCD1 ALDH1A1 747/4885TSHR 79/4885TRIM24 4686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.